All In MedTech

Device Trial Radar · NCT03029299

Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting

Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Apr 4, 2017

Primary completion

Sep 15, 2017

Study completion Sep 15, 2017

Sponsor

Lead sponsor
BioFire Diagnostics, LLCNot on our public-company list
Sponsor type
Industry
Collaborators
University of California, Los Angeles
First posted
Jan 24, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BioFire Diagnostics, LLC (BioFire; a bioMerieux company), has developed a multiplexed molecular-based in vitro diagnostic platform for infectious disease testing known as the FilmArray. The FilmArray Respiratory Panel (RP) EZ is a test designed for use with the FilmArray 2.0 EZ Configuration instrument that identifies common bacterial and viral microorganisms associated with respiratory tract infections from a nasopharyngeal swab (NPS) specimen collected in viral transport media (VTM). The RP EZ was granted CLIA-waived classification by the FDA in October 2016 and is the first highly-multiplexed molecular test to receive this designation. The purpose of this study is to measure patient outcomes following implementation of the RP EZ test and to also gather data about physician office workflow and user interactions with the device. These data will be used to understand how the adoption of such tests may influence patient care in the CLIA-waived setting.

Conditions

  • Respiratory Tract Infections

Interventions

  • FilmArray RP EZDevice

    Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time duration from initial visit to receipt of appropriate therapyTime frame: through study completion, an average of one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.